Introduction
Omeprazole is a new substituted benzimidazole (fig 1) . Substituted benzimidazoles inhibit the action of the enzyme H+K+ adenosinetriphosphatase (ATPase), which is postulated to be the proton pump of the parietal cell.'-7 Omeprazole inhibits both basal and pentagastrin stimulated acid secretion in normal In earlier 24 hour studies with cimetidinell 12 and ranitidine'3 we defined the effective dose of these antisecretory drugs before the start of clinical trials: both H, receptor antagonists decrease mean intragastric hydrogen ion activity by approximately two thirds over 24 hours in patients with duodenal ulcer. Omeprazole appears to be a more potent inhibitor of acid secretion than either cimetidine or ranitidine.' In the present study we measured the effect of a daily oral dose of omeprazole 30 mg on 24 hour intragastric acidity.
Patients and methods
Nine men with endoscopically diagnosed duodenal ulcers in remission were studied. two weeks before the start of the study. All patients gave written informed consent, and the study was approved by the hospital ethical committee. Each patient was studied on two separate occasions one week apart. The experimental design was similar to that previously described, with dietary and environmental conditions identical on both study days."4 All patients were admitted at a weekend to the day ward. Each study started at 0800, when a 10 French gauge Salem sump nasogastric tube (Argyle Medical) was passed and its tip positioned under x ray control to lie in the most dependent part of the stomach.
During the day the patients ate normal meals, remained ambulant within the ward, and were entertained with television, films, newspapers, and magazines. The menu (breakfast, coffee, lunch, tea, dinner, and a non-alcoholic nightcap) was identical on both study days. The pH of the meals, homogenised for laboratory analysis, was 5 05, 6 36, 5 70, 4-64, 5 16, and 6 13 respectively. Those patients who smoked kept a record of cigarette consumption throughout the first experimental day and adhered to the established pattern on the subsequent study day.
Starting at 0900 on the morning of each study day 5-10 ml samples of gastric contents were aspirated hourly for 24 hours. The pH of each sample was measured immediately to the nearest 0-01 pH unit with a glass electrode (Russell pH Ltd) and a digital pH meter (Digital 11 1, Corning-Eel). The electrode was calibrated with standard buffers (pH 7 00, 4-01, 1-68; Radiometer, Copenhagen) before, during, and after assessment of each batch of nine samples. The measurements of intragastric acidity were expressed in terms of either pH or hydrogen ion activity.
On the first study day the patients received no drugs. Oral omeprazole was started at 0900 after the first study day, and each patient took omeprazole 30 mg daily before breakfast for seven days. The 
Results
The two studies were well tolerated by all the patients. No abnormalities in the laboratory safety studies or clinical examination were observed. The patients did not report any serious unwanted acute effects, but one developed a lichenoid eruption 11 days after stopping the drug. A biopsy specimen of the affected skin showed non-specific changes.
Omeprazole 30 mg daily for one week produced a profound decrease in intragastric acidity in all nine patients. Figure 2 shows the mean hourly intragastric hydrogen ion activity in all the patients on the two experimental days; the activity was significantly lower at every measurement when patients were taking omeprazole (p < 0-001). The mean (SEM) 24 hour intragastric hydrogen ion activity before treatment of 38 50 (2 03) mmol(mEq)/l fell significantly to 1-95 (0-46) mmol/l during treatment (p < 0-001). Figure 3 shows all the individual measurements of pH made during the two 24 hour periods before and during treatment with omeprazole.
Before treatment only 26 (1200) of the measurements were greater than 3-00 (hydrogen ion activity < 1-0 mmol/l), compared with 185 (860 ') of the measurements during treatment. The median pH was 14 before treatment with omeprazole, rising to 5-3 during treatment.
4. potent as cimetidine on a weight for weight basis.'3 15 We studied cimetidine and ranitidine in an earlier series of 24 hour experiments,"3 in which patients were treated with H2antagonists
5.
for only 24 hours before study. As there is no evidence that H, blockade is cumulative during prolonged treatment these earlier findings may be compared with the present data. Figure 4 shows the individual pH values in 10 patients with duodenal ulcer treated by mouth with placebo, ranitidine 300 mg daily, or cimetidine 1 g daily. The distribution of pH values in the placebo group in that study (fig 4) was virtually identical with that in the present patients before treatment (fig 3) . The mean 24 hour intragastric hydrogen ion activity in the original placebo group was 41-8 mmol/l, compared with 38-5 mmol/l in the present study; the median pH in both studies was 1-4. As the pattern of intragastric acidity in the two groups of untreated duodenal patients was similar it is valid to compare the effectiveness of the different types of antisecretory drugs used in the two studies.
Cimetidine 1 g/day and ranitidine 300 mg/day significantly decreased mean 24 hour intragastric hydrogen ion activity by 48% and 69% respectively, whereas omeprazole 30 mg/day caused a 95% decrease. Treatment with cimetidine caused the median 24 hour intragastric pH to rise from 14 to 1-7 (a twofold decrease in acidity), whereas during treatment with ranitidine the median pH rose to 2-4 (a 10-fold decrease). After one week of treatment with omeprazole 30 mg daily the median 24 hour intragastric pH had risen to 5-3 (an 8000-fold decrease in acidity). During treatment with omeprazole, cimetidine, or ranitidine intragastric pH was greater than 3-0 in 86%, 12%, and 24% samples, respectively. Whichever way the data are analysed,'6 omeprazole suppressed intragastric acidity much more effectively than either of the H, receptor antagonists at the optimum doses tested.
During treatment with omeprazole 30 mg daily intragastric acidity was completely eliminated during the later afternoon and early evening, a period during which acidity is poorly controlled by H, blockers."'-14 Even though omeprazole was given as a single dose in the morning, intragastric acidity during the following night was negligible.
The beneficial effects of H, antagonists are thought to depend on inhibition of gastric acid secretion. Because of its more profound antisecretory activity omeprazole may possibly produce superior clinical results. Better patient compliance might also be expected with once daily dosage. About 70-800,' of duodenal ulcers heal during one month of treatment with either cimetidine or ranitidine' 7 -19; improved clinical results may be possible with omeprazole.
Treatment with omeprazole for one week was free from any unwanted acute effects. Animal studies suggest that H+K+ adenosinetriphosphatase is found only in the gastric parietal cells,20 but further investigation is needed in man. A sustained decrease in intragastric acidity might be expected to permit bacterial contamination of the stomach,2" but this is unlikely to be harmful if full dose treatment with omeprazole is prescribed for only a short time, until ulcer healing occurs.
The results of the present study, under conditions that approximate to everyday life, show that once daily omeprazole is a potent inhibitor of intragastric acidity. Clinical trials are indicated in those conditions in which control of gastric acid secretion is thought to be beneficial.
